These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 34583312)
1. Synthesis and antiviral activity of fatty acyl conjugates of remdesivir against severe acute respiratory syndrome coronavirus 2 and Ebola virus. El-Sayed NS; Jureka AS; Edwards MR; Lohan S; Williams CG; Keiser PT; Davey RA; Totonchy J; Tiwari RK; Basler CF; Parang K Eur J Med Chem; 2021 Dec; 226():113862. PubMed ID: 34583312 [TBL] [Abstract][Full Text] [Related]
2. Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency. Gordon CJ; Tchesnokov EP; Woolner E; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 May; 295(20):6785-6797. PubMed ID: 32284326 [TBL] [Abstract][Full Text] [Related]
3. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. Gordon CJ; Tchesnokov EP; Feng JY; Porter DP; Götte M J Biol Chem; 2020 Apr; 295(15):4773-4779. PubMed ID: 32094225 [TBL] [Abstract][Full Text] [Related]
5. Efficient incorporation and template-dependent polymerase inhibition are major determinants for the broad-spectrum antiviral activity of remdesivir. Gordon CJ; Lee HW; Tchesnokov EP; Perry JK; Feng JY; Bilello JP; Porter DP; Götte M J Biol Chem; 2022 Feb; 298(2):101529. PubMed ID: 34953856 [TBL] [Abstract][Full Text] [Related]
6. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment. Khazir J; Maqbool T; Mir BA Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800 [TBL] [Abstract][Full Text] [Related]
7. Discovery and Evaluation of Entry Inhibitors for SARS-CoV-2 and Its Emerging Variants. Acharya A; Pandey K; Thurman M; Klug E; Trivedi J; Sharma K; Lorson CL; Singh K; Byrareddy SN J Virol; 2021 Nov; 95(24):e0143721. PubMed ID: 34550770 [TBL] [Abstract][Full Text] [Related]
8. Genetic conservation of SARS-CoV-2 RNA replication complex in globally circulating isolates and recently emerged variants from humans and minks suggests minimal pre-existing resistance to remdesivir. Martin R; Li J; Parvangada A; Perry J; Cihlar T; Mo H; Porter D; Svarovskaia E Antiviral Res; 2021 Apr; 188():105033. PubMed ID: 33549572 [TBL] [Abstract][Full Text] [Related]
9. Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action. Tchesnokov EP; Gordon CJ; Woolner E; Kocinkova D; Perry JK; Feng JY; Porter DP; Götte M J Biol Chem; 2020 Nov; 295(47):16156-16165. PubMed ID: 32967965 [TBL] [Abstract][Full Text] [Related]
10. Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type. Mohammad A; Al-Mulla F; Wei DQ; Abubaker J Biomolecules; 2021 Jun; 11(7):. PubMed ID: 34206274 [TBL] [Abstract][Full Text] [Related]
12. Remdesivir: A beacon of hope from Ebola virus disease to COVID-19. Nili A; Farbod A; Neishabouri A; Mozafarihashjin M; Tavakolpour S; Mahmoudi H Rev Med Virol; 2020 Nov; 30(6):1-13. PubMed ID: 33210457 [TBL] [Abstract][Full Text] [Related]
13. Inhibition of SARS-CoV-2 polymerase by nucleotide analogs from a single-molecule perspective. Seifert M; Bera SC; van Nies P; Kirchdoerfer RN; Shannon A; Le TT; Meng X; Xia H; Wood JM; Harris LD; Papini FS; Arnold JJ; Almo S; Grove TL; Shi PY; Xiang Y; Canard B; Depken M; Cameron CE; Dulin D Elife; 2021 Oct; 10():. PubMed ID: 34617885 [TBL] [Abstract][Full Text] [Related]
14. An overview of the preclinical discovery and development of remdesivir for the treatment of coronavirus disease 2019 (COVID-19). Pagliano P; Sellitto C; Scarpati G; Ascione T; Conti V; Franci G; Piazza O; Filippelli A Expert Opin Drug Discov; 2022 Jan; 17(1):9-18. PubMed ID: 34412564 [TBL] [Abstract][Full Text] [Related]
15. In vitro selection of Remdesivir resistance suggests evolutionary predictability of SARS-CoV-2. Szemiel AM; Merits A; Orton RJ; MacLean OA; Pinto RM; Wickenhagen A; Lieber G; Turnbull ML; Wang S; Furnon W; Suarez NM; Mair D; da Silva Filipe A; Willett BJ; Wilson SJ; Patel AH; Thomson EC; Palmarini M; Kohl A; Stewart ME PLoS Pathog; 2021 Sep; 17(9):e1009929. PubMed ID: 34534263 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of Remdesivir, a SARS-CoV-2 Replication Inhibitor. Humeniuk R; Mathias A; Kirby BJ; Lutz JD; Cao H; Osinusi A; Babusis D; Porter D; Wei X; Ling J; Reddy YS; German P Clin Pharmacokinet; 2021 May; 60(5):569-583. PubMed ID: 33782830 [TBL] [Abstract][Full Text] [Related]
17. In vitro activity of itraconazole against SARS-CoV-2. Van Damme E; De Meyer S; Bojkova D; Ciesek S; Cinatl J; De Jonghe S; Jochmans D; Leyssen P; Buyck C; Neyts J; Van Loock M J Med Virol; 2021 Jul; 93(7):4454-4460. PubMed ID: 33666253 [TBL] [Abstract][Full Text] [Related]
18. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. Pitts J; Li J; Perry JK; Du Pont V; Riola N; Rodriguez L; Lu X; Kurhade C; Xie X; Camus G; Manhas S; Martin R; Shi PY; Cihlar T; Porter DP; Mo H; Maiorova E; Bilello JP Antimicrob Agents Chemother; 2022 Jun; 66(6):e0022222. PubMed ID: 35532238 [TBL] [Abstract][Full Text] [Related]
19. Novel quinolone derivatives targeting human dihydroorotate dehydrogenase suppress Ebola virus infection in vitro. Gong M; Yang Y; Huang Y; Gan T; Wu Y; Gao H; Li Q; Nie J; Huang W; Wang Y; Zhang R; Zhong J; Deng F; Rao Y; Ding Q Antiviral Res; 2021 Oct; 194():105161. PubMed ID: 34391783 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Antiviral Activity of Gemcitabine with 2'-Fluoro-2'-Deoxycytidine and Combination Therapy with Remdesivir against SARS-CoV-2. Jang Y; Shin JS; Lee MK; Jung E; An T; Kim UI; Kim K; Kim M Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33557278 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]